Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 35, Issue 6, Pages 1129-1145Publisher
SPRINGER
DOI: 10.1007/s10557-020-07018-5
Keywords
Atherosclerosis; Idebenone; SIRT3-SOD2-mtROS pathway; Antioxidants; NLPR3; Inflammation
Funding
- Taishan Scholars Program of Shandong Province and Policy [2019GXRC050]
Ask authors/readers for more resources
This study demonstrated that idebenone acts as a mitochondrial protective agent by inhibiting NLPR3 activation via the SIRT3-SOD2-mtROS pathway, significantly reducing plaque burden and plaque size while stabilizing atherosclerotic plaques. Up-regulation and down-regulation of proteins were found in idebenone-treated mice, with SIRT3, SOD2, and NLRP3 expression significantly regulated both in vivo and in vitro. Furthermore, idebenone protected against endothelial cell damage and inhibited the production of mitochondrial reactive oxygen species in cholesterol-treated HUVECs.
Purpose Atherosclerosis, a chronic disease of the arteries, results from pathological processes including the accumulation and aggregation of oxidized low-density lipoprotein (oxLDL) in the vessel walls, development of neointima, formation of a fibrous cap, and migration of immune cells to damaged vascular endothelium. Recent studies have shown that mitochondrial dysfunction is closely associated with the development and progression of atherosclerosis. Idebenone, a short-chain benzoquinone similar in structure to coenzyme Q10, can effectively clear oxygen free radicals as an electron carrier and antioxidant. In the present study, we aim to investigate weather idebenone protects against atherosclerosis in apolipoprotein E-deficient (apoE-/-) mice. Methods apoE-/- mice receiving a high-fat diet (HFD) were treated with idebenone for 16 weeks. A total of 60 mice were randomized into the following four groups: (1) HFD, (2) HFD and low-dose idebenone (100 mg/kg/d), (3) HFD and medium-dose idebenone (200 mg/kg/d), and (4) HFD and high-dose (400 mg/kg/d). Proteomic analysis was performed between the HFD and idebenone-high-dose group. Plaque analysis was carried out by histological and immunohistochemical staining. Western blot, TUNEL staining, and MitoSOX assays were performed in human umbilical vein endothelial cells (HUVECs) to investigate the SIRT3-SOD2-mtROS pathway. Results Histological and morphological analysis demonstrated that idebenone significantly reduced plaque burden and plaque size. Idebenone treatment effectively stabilized the atherosclerotic plaques. In mice treated with idebenone, 351 up-regulated and 379 down-regulated proteins were found to be significantly altered in proteomic analysis. In particular, the expression of SIRT3, SOD2, and NLRP3 was significantly regulated in the idebenone treatment groups compared with the HFD group both in vivo and in vitro. We further confirmed that idebenone protected against endothelial cell damage and inhibited the production of mitochondrial reactive oxygen species (mtROS) in cholesterol-treated HUVECs. Conclusions We demonstrated that idebenone acted as a mitochondrial protective agent by inhibiting the activation of NLPR3 via the SIRT3-SOD2-mtROS pathway. Idebenone may be a promising therapy for patients with atherosclerosis by improving mitochondrial dysfunction and inhibiting oxidative stress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available